MEK1 (MAPKK1) polyclonal, anti-human

Protein Family: Enzymes, Protein Kinases

Pathway and Disease: Signal Transduction, Cancers, Cell Growth and Death,Cell Motility, Metabolic Disorders, Cell Communication, Immune System, Endocrine System, Nervous and Sensory Systems, Neurodegenerative Disorders, Development and Behavior

Description:
MEK1 (MAPKK1) catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. MEKI (MAPKK1) activates ERK1 and ERK2 MAP kinases, enzymes which are involved in numerous signal transduction pathways. Defects in MEK1 (MAPKK1) are a cause of cardiofaciocutaneous syndrome (CFC syndrome), also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation.

Alternate Names: MAPKK1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK1, MAP2K1, PRKMK1

Application Notes: E: 1:1,000-1:100,000; WB: 1:100-1:1,1000; IHC: 1:50-1:250

Accession No.: Q02750

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human MEK1 (MAPKK1) .

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 0.5 % BSA with 0.09% sodium azide. Antibody was purified by immunogen-affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.